NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

17 Nov 2026🟠 Likely Overhyped
Share𝕏inf

Annovis Bio’s Phase 3 Alzheimer’s trial receives a second positive safety review from the DSMB.

What the company is saying

Annovis Bio, Inc. is highlighting a second consecutive positive safety recommendation from the independent Data and Safety Monitoring Board for its pivotal Phase 3 DUET-AD trial in early Alzheimer’s disease. The company frames this as a major milestone, emphasizing the scale—861 patients evaluated as of September 22, 2026—and the DSMB’s recommendation to continue the trial without modification. Chief Scientific Officer Cheng Fang, Ph.D., asserts that this outcome reinforces confidence in buntanetap’s safety profile, directly linking the DSMB’s feedback to the company’s narrative of progress and readiness for regulatory submission. Annovis stresses that this milestone comes as it approaches the 6-month data readout and plans to report detailed safety and symptomatic results in March 2027. The announcement is structured to convey steady operational progress and regulatory momentum, but efficacy data is not discussed. The tone is confident and forward-looking, with safety emphasized as the current foundation for future regulatory steps.

What the data suggests

The DSMB’s second positive safety recommendation for DUET-AD, based on data from 861 patients, confirms that no safety concerns have arisen to date that would warrant modifying or halting the trial. The trial remains on schedule, with the last patient’s 6-month visit expected by December 31, 2026, database lock on February 8, 2027, and topline 6-month results anticipated in March 2027. The company provides clear operational milestones and patient enrollment figures, demonstrating large-scale trial execution. However, the announcement contains no efficacy data, no financial metrics, and no information on regulatory submissions beyond intentions. The evidence supports continued trial safety but does not address whether buntanetap is effective in treating Alzheimer’s disease. The company’s claims about halting disease progression and improving cognitive and motor functions remain unsubstantiated by disclosed data.

Analysis

The announcement's tone is upbeat, emphasizing a 'second consecutive positive recommendation' from the DSMB for the DUET-AD Phase 3 trial. This is a meaningful operational milestone, but the language inflates the signal by extrapolating safety review outcomes into broader confidence in the drug's efficacy and future regulatory success, despite no efficacy data being disclosed. Most key claims are forward-looking, including plans to report results, expectations for regulatory submission, and aspirational statements about halting disease progression. The actual measurable progress is limited to the DSMB's safety recommendation and trial operational milestones (patient numbers, timeline). No financial or efficacy data are provided, and the next major catalyst (6-month topline results) is not expected until March 2027, making the execution distance long-term. There is no explicit mention of a large capital outlay in this update, so the capital intensity flag is false.

Risk flags

  • ●Efficacy risk remains high, as no clinical efficacy data have been disclosed; the DSMB’s remit is limited to safety, so the trial could still fail on efficacy endpoints, which would materially impact the asset’s value.
  • ●Timeline risk is present, as the next major data release is not expected until March 2027; any delay in patient visits, database lock, or analysis could push value realization further out, affecting investor expectations and funding needs.
  • ●Financial opacity is a concern, as the company provides no information on cash position, burn rate, or funding runway; this limits an investor’s ability to assess whether Annovis can sustain operations through the next critical milestones.
  • ●Regulatory uncertainty persists, since the company references preparations for regulatory submission but has not disclosed any engagement, feedback, or acceptance from regulatory agencies; approval is contingent on both safety and efficacy data yet to be seen.

Bottom line

Annovis Bio’s DUET-AD Phase 3 trial for early Alzheimer’s disease has cleared another safety hurdle, with the DSMB recommending the study continue unchanged after reviewing data from 861 patients. This supports the company’s narrative of operational progress and safety at scale, but there is no new information on whether buntanetap is effective. The next real catalyst—the 6-month topline results—is not due until March 2027, so investors face a multi-month wait for efficacy data that could drive valuation. The absence of financial disclosures leaves open questions about the company’s ability to fund operations through these milestones. The most important takeaway is that while safety is confirmed, the investment case now hinges entirely on forthcoming efficacy results and the company’s financial runway. Investors should focus on the March 2027 data readout as the decisive event.

Announcement summary

(NYSE:ANVS) Annovis Bio, Inc. announced that an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for DUET-AD, the company’s pivotal Phase 3 trial in early Alzheimer’s disease (AD), following a review of the study’s safety data. This 12-month DSMB review follows a previous positive 6-month feedback announced in February 2026. The DSMB recommended that the DUET-AD trial continue without modification, based on data accumulated through September 22, 2026, from 861 patients at different stages of dosing. Cheng Fang, Ph.D., Chief Scientific Officer at Annovis, stated that a second positive recommendation in such a large population reinforces confidence in buntanetap’s safety profile. The company highlighted that this milestone comes as they approach the 6-month data readout and prepare for regulatory submission. Annovis plans to report detailed DUET-AD safety outcomes alongside the 6-month symptomatic results in March. The DUET-AD trial (NCT06709014) remains on track, with the last patient, last visit for the 6-month treatment period expected on December 31, 2026. The database lock is scheduled for February 8, 2027. The 6-month topline results are expected in March 2027. Buntanetap, formerly known as posiphen, is Annovis’s lead drug candidate and is an investigational once-daily oral therapy. Buntanetap inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. The company is developing buntanetap for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Annovis states that by addressing the underlying causes of neurodegeneration, they aim to halt disease progression and improve cognitive and motor functions in patients.

Disagree with this article?

Ctrl + Enter to submit